NCT05785156

Diagnostic and Prognostic Value of New Quick Tests of Action Slowing in Stroke and in Cognitive Neurodegenerative Disease

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 129 (estimated)
• Sponsor: Centre Hospitalier Universitaire, Amiens · Academic / Other
• Sex: All
• Age: 40 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

A large series of recent studies have documented the frequency of the slowing of the action in brain diseases, especially vascular and neurodegenerative diseases. In stroke, the predictive value of action slowing at the acute phase for predicting post-stroke functional outcome remains poorly investigated. In neurodegenerative diseases, the diagnostic relevance of the slowing at the prodromal stage remains unknown and this diagnostic requires new tests. Finally, in terms of anatomical determinants, few studies have studied the determinants of action slowing. The objectives of this project are to Determine the diagnostic and prognostic value of action slowing assessed with new quick tests in patients with acute stroke (Neurovascular Unit) and cognitive neurodegenerative disorders (Alzheimer Disease (AD), Lewy Body disease (LBD), Fronto Temporal lobar degeneration (FTLD), Cortico Basal Degeneration (CBD) and Progressive Supra Nuclear Palsy (PSNP)) and to define the lesion determinants with VBM and VLSM

Conditions

• Stroke
• Action Speed
• Dementia Mild Cognitive Impairment
• Alzheimer Disease

Interventions

Type	Name	Description
OTHER	quick tests	New quick tests are * Batterie MindPlus (Brevet n° FR1908081, Suarez 2019) is a quick reaction time battery and * Minimal Cognitive Evaluation (MCE) test (Sardi et al, 2019) is a cognitive screening tests including a specific assessment of slowing

Timeline

• Start date: 2021-07-16
• Primary completion: 2024-07-01
• Completion: 2025-07-01
• First posted: 2023-03-27
• Last updated: 2023-03-27

Locations

1 site across 1 country: France